21:22 , Jul 2, 2019 |  BC Extra  |  Financial News

July 2 Financial Quick Takes: Suspension continues for Woodford fund; plus CRUK, Codiak and Amarin

Woodford extends fund suspension  Woodford Investment Management Ltd. extended to July 29 the suspension of trading in its flagship fund, Woodford Equity Income Fund. The extension’s purpose is to allow the fund manager more time...
01:39 , Jun 29, 2019 |  BioCentury  |  Finance

Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split. After recovering at the start of the...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
21:41 , May 29, 2019 |  BC Extra  |  Company News

May 29 Company Quick Takes: Priority Review for Amarin's Vascepa; plus Tuhura-Moffitt Cancer Center deal and more

Priority Review for Vascepa to reduce CV risk  Amarin Corp. plc (NASDAQ:AMRN) gained $1.98 (12%) to $18.99 on Wednesday after FDA accepted and granted Priority Review to an sNDA for Vascepa icosapent ethyl to reduce...
13:35 , Mar 22, 2019 |  BC Week In Review  |  Clinical News

Amarin's Vascepa reduces total CV events by 30% in REDUCE-IT

Amarin reported additional data from the Phase III REDUCE-IT trial of Vascepa icosapent ethyl to reduce major adverse cardiovascular events (MACE) showing that the drug led to a 30% reduction in total CV events vs....
01:15 , Jan 12, 2019 |  BioCentury  |  Finance

JPM jump-starts 2019

About three quarters of the more than 200 biopharma companies presenting at the 2019 J.P. Morgan Healthcare Conference saw their stock prices rise last week. Leading the pack was the 53% jump by Insmed Inc....
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
04:32 , Nov 30, 2018 |  BC Week In Review  |  Financial News

Amarin raises $200M ahead of Vascepa push

Amarin Corp. plc (NASDAQ:AMRN) raised $200 million on Nov. 26 in a follow-on as it prepares to add cardioprotective data to the label of omega-3 therapy Vascepa icosapent ethyl following a readout from the Phase...
18:57 , Nov 27, 2018 |  BC Extra  |  Financial News

Amarin raises $200M ahead of Vascepa push

Amarin Corp. plc (NASDAQ:AMRN) raised $200 million in a follow-on late Monday as it prepares to add cardioprotective data to the label of omega-3 therapy Vascepa icosapent ethyl following a readout from the Phase III...
16:04 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Amarin details primary endpoint data for Vascepa, addresses placebo concern

Amarin Corp. plc. (NASDAQ:AMRN) presented detailed primary endpoint data from the Phase III REDUCE-IT trial of Vascepa icosapent ethyl to reduce major adverse cardiovascular events (MACE) and addressed concerns that the mineral oil used in...